drugset / Trial / NCT01158118

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

NCT01158118

Phase 2 Completed 48 enrolled Washington University School of Medicine
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will gather information about the combination the drugs plerixafor with sargramostim in donors of blood-forming cells (stem cells). These stem cells will be collected from the donor and transplanted into their sibling. The investigators believe that the two drugs together will provide enough stem cells for transplantation and may also reduce the risk of graft versus host disease.

Timeline

Start
2011-04-01
Primary completion
2014-01-15
Completion
2016-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Plerixafor Small molecule 320 ug/kg Intravenous
Subject sargramostim Protein / enzyme biologic 5 ug/kg
Subject sargramostim Protein / enzyme biologic 10 ug/kg